CMRX Quote, Financials, Valuation and Earnings

Cumberland Pharmaceuticals has a net margin of -87996.15% compared to Chimerix's net margin of -16.99%. Chimerix's return on equity of -48.22% beat Cumberland Pharmaceuticals's return on equity of -38.11%.

Chimerix has a consensus price target of --, signalling upside risk potential of 142.78%. On the other hand Cumberland Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 266.38%. Given that Cumberland Pharmaceuticals has higher upside potential than Chimerix, analysts believe Cumberland Pharmaceuticals is more attractive than Chimerix.

Chimerix has a beta of 1.018, which suggesting that the stock is 1.827% more volatile than S&P 500. In comparison Cumberland Pharmaceuticals has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.15%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cumberland Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Cumberland Pharmaceuticals pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $26K, which are smaller than Cumberland Pharmaceuticals quarterly revenues of $9.1M. Chimerix's net income of -$22.9M is lower than Cumberland Pharmaceuticals's net income of -$1.5M. Notably, Chimerix's price-to-earnings ratio is -- while Cumberland Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 0.89x for Cumberland Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions has a net margin of -87996.15% compared to Chimerix's net margin of 40.45%. Chimerix's return on equity of -48.22% beat Emergent BioSolutions's return on equity of -35.94%.

Chimerix has a consensus price target of --, signalling upside risk potential of 142.78%. On the other hand Emergent BioSolutions has an analysts' consensus of $12.00 which suggests that it could grow by 45.1%. Given that Chimerix has higher upside potential than Emergent BioSolutions, analysts believe Chimerix is more attractive than Emergent BioSolutions.

Chimerix has a beta of 1.018, which suggesting that the stock is 1.827% more volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.352%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $26K, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. Chimerix's net income of -$22.9M is lower than Emergent BioSolutions's net income of $114.8M. Notably, Chimerix's price-to-earnings ratio is -- while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 0.40x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

Geovax Labs has a net margin of -87996.15% compared to Chimerix's net margin of -208.48%. Chimerix's return on equity of -48.22% beat Geovax Labs's return on equity of -575.49%.

Chimerix has a consensus price target of --, signalling upside risk potential of 142.78%. On the other hand Geovax Labs has an analysts' consensus of $14.60 which suggests that it could grow by 493.5%. Given that Geovax Labs has higher upside potential than Chimerix, analysts believe Geovax Labs is more attractive than Chimerix.

Chimerix has a beta of 1.018, which suggesting that the stock is 1.827% more volatile than S&P 500. In comparison Geovax Labs has a beta of 3.242, suggesting its more volatile than the S&P 500 by 224.241%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geovax Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Geovax Labs pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $26K, which are smaller than Geovax Labs quarterly revenues of $2.8M. Chimerix's net income of -$22.9M is lower than Geovax Labs's net income of -$5.8M. Notably, Chimerix's price-to-earnings ratio is -- while Geovax Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus -- for Geovax Labs. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -87996.15% compared to Chimerix's net margin of -503.65%. Chimerix's return on equity of -48.22% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

Chimerix has a consensus price target of --, signalling upside risk potential of 142.78%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $5.83 which suggests that it could grow by 1627.88%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Chimerix, analysts believe Tonix Pharmaceuticals Holding is more attractive than Chimerix.

Chimerix has a beta of 1.018, which suggesting that the stock is 1.827% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.214%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $26K, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. Chimerix's net income of -$22.9M is lower than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, Chimerix's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 0.53x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.